Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Budesonide inhalation - Aquilon Pharma

Drug Profile

Budesonide inhalation - Aquilon Pharma

Alternative Names: AQ-001S

Latest Information Update: 23 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aquilon Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antivirals; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II SARS-CoV-2 acute respiratory disease
  • Phase I/II Asthma

Most Recent Events

  • 31 Jan 2023 Aquilon Pharmaceuticals completes the I/II BOREAS trial in Asthma in Belgium (NCT04933383; EudraCT2019-002849-38)
  • 21 Dec 2022 Aquilon Pharmaceuticals terminates a phase-II trial in SARS-COV-2 acute respiratory disease in Belgium (Inhalation) due to lack of patient enrolment (EudraCT2021-000014-42; NCT05000346)
  • 21 Feb 2022 Aquilon Pharmaceuticals completes the BORA trial in SARS-COV-2 acute respiratory disease (In volunteers) in Bulgaria (Inhalation) (NCT05148312)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top